Homologous recombination (HR) is a principal support pathway for DNA replication and for recovery from DNA breaks and interstrand crosslinks, making it a rational target for inhibition in cancer therapy. The ATPase RAD54 functions in molecular events that promote DNA sequencepreservation during HR-mediated damage repair, including homology search, DNA strand exchange, and transition to DNA repair synthesis within a displacement loop intermediate. We developed a high-throughput biochemical screen to identify small-molecule inhibitors of human RAD54, using a phosphate detection assay to monitor RAD54 ATPase activity in the presence of double-stranded DNA (dsDNA). After filtering potential DNA intercalators and 'frequent hitters,' we identified two chemotypes that reproducibly inhibited RAD54 ATPase in vitro. We evaluated these chemotypes for inhibition of RAD54-dsDNA binding and cancer cell survival. A halogenated carbazole/dihydroacridine scaffold inhibited a panel of SWI2/SNF2 -related ATPases but not VCP/p97, an unrelated ATPase. Small molecules that interfere with key steps in HRsuch as inhibitors of RAD54-may expose DNA repair-dependent vulnerabilities in cancer cells.
INTRODUCTION
Homologous recombination (HR) is an evolutionarily ancient DNA repair pathway with functions in replication-fork support, DNA double-strand break repair and interstrand crosslink repair 1 . Some cancers exploit HR for survival when confronted with intrinsic replication stress, deficient alternative repair pathways, and/or chemotherapeutic-and radiation-induced DNA damage 2, 3 . Hence, genetic or chemical disruption of critical steps in HR could kill cancer cells that have inherent DNA-repair deficiencies, and could sensitize cells to treatments that cause DNA damage or interfere with replication 4, 5 .
In HR, a span of single-stranded DNA (ssDNA) references a related DNA sequence elsewhere in the genome to restore lost or damaged sequence information. In eukaryotes, the ATPases RAD51 and RAD54 are required for homology search, recognition, and DNA strand exchange 6 .
RAD51, RAD51 paralogs and associated factors assemble on ssDNA, creating a nucleoprotein filament that catalyzes the identification of a homologous double-stranded DNA (dsDNA)
sequence, typically at an allelic site. Base-pairing between the RAD51-coated ssDNA and its dsDNA complement results in DNA strand exchange, the conversion of a RAD51-bound filament and its dsDNA target to a RAD51-bound heteroduplex DNA (hDNA) within a displacement loop (D-loop) 7 . When RAD51 dissociates from hDNA, the 3'-hydroxyl of the invading ssDNA can prime DNA synthesis, using the complementary strand in the hDNA as a template to restore missing sequence. Diverse protein factors regulate RAD51 filament assembly, homology search, DNA strand exchange, and the transition to DNA repair synthesis 8 , suggesting that multiple enzymes and stages in HR could be targeted for inhibition in cancer cells.
At the key transition between homologous sequence identification and DNA repair synthesis, Dloop formation and RAD51 dissociation from hDNA are catalyzed by RAD54 9 , a dsDNAdependent, multimeric ATPase that functionally associates with the RAD51 nucleoprotein filament 10, 11 . Whereas RAD51 exhibits slow ATPase kinetics on both ssDNA and dsDNA (kcat ~0.4 ATP RAD51 -1 min
), RAD54 hydrolyzes ATP only in the presence of dsDNA, with roughly 2,500-fold faster kinetics than RAD51 (kcat ~10 3 ATP RAD54 -1 min -1 ) [12] [13] [14] . Both ATPases coordinate the transition from synapsis (defined by a RAD51-bound, three-stranded DNA intermediate) to post-synapsis (hDNA 3'-terminus competent to prime DNA repair synthesis), as RAD54 specifically dissociates the ADP-bound conformation of RAD51 1, 12 and RAD54 ATPase activity is stimulated by interaction with RAD51 on dsDNA 15 . RAD54 modulation of RAD51-dsDNA interaction is consistent with the hallmark activities of eukaryotic SWI2/SNF2 ATPases, namely remodeling of specific protein-DNA interactions 16 . In vivo studies in Saccharomyces cerevisiae demonstrate that although Rad51 filaments assemble and Rad51 can be recovered from donor loci in the absence of Rad54, DNA synthesis from the donor template requires the ATPase activity of Rad54 17 . Altogether, these observations suggest that RAD54 is a critical modulator of transitional step(s) between homologous pairing and the synthesis-dependent recovery of homologous sequence.
We sought to discover small-molecule inhibitors of RAD54 to seed an anti-cancer drugdiscovery effort. Using a colorimetric malachite green phosphate detection assay 18 , we screened >106,000 small molecules for inhibition of ATPase activity in the presence of dsDNA, and retested 310 molecules from the primary screen using an orthogonal luminescent ATPase assay that reports on ADP levels (ADP-Glo and related dihydroacridine analogs were identified as inhibitors of RAD54 and related SWI2/SNF2 ATPases.
MATERIALS AND METHODS
Human RAD54 purification and ATPase activity-Human RAD54 was purified as a GST-fusion from baculovirus-infected Sf9 cells; ATPase activity was entirely dsDNA-dependent and promoted D-loop formation with RAD51 in vitro as previously described 14, 19 . ATPase selectivity assays-IC50 values for ATPase activities of S. cerevisiae Rad54, Rdh54/Tid1, H. sapiens SMARCAL1, HLTF, VCP/p97 and E. coli RecA were determined by MG assay as described for RAD54, with modifications described in Supplement (Supp. Fig. 18 ).
Malachite green (MG) primary assay-A

RESULTS AND DISCUSSION
Cancer is frequently treated using combination approaches to target multiple molecular pathways that drive proliferation, malignancy, and/or resistance to first-line therapies 25 . Several arguments point to HR as a candidate target for therapeutic inhibition in cancer. First, during S-phase, proliferating cells prioritize HR above the alternative DSB repair pathway non-homologous endjoining (NHEJ)
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, and HR aids DNA replication forks at template impasses or within complex genomic regions (e.g., repeats) 26 . Second, outside of HR, only single-strand annealing (SSA) between direct repeats can repair extensively resected ssDNA, presenting constraints for repair of resected ssDNA in cancer cells 27 . Third, chemotherapies and radiation cause DNA damage normally repaired by HR (e.g., interstrand crosslinks (ICLs), one-/two-ended DSBs, singlestranded gaps (Supp. Fig. 1 
RAD54 inhibitor screen
Malachite green assay. We developed a malachite green phosphate-detection assay in 384-well format to screen for small molecules that inhibit RAD54 ATPase activity in the presence of dsDNA (Supp. Fig. 2 ). Human RAD54 (hereafter RAD54) was purified as a GST-fusion from baculovirus-infected Sf9 cells. The MG assay was optimized for MG signal stability (Supp. Fig.   2 ) and enzyme activity (Supp. Fig. 3 ). Under the assay conditions (2.5 nM RAD54, 125 nM (bp) pUC19, 1 mM ATP, 3 mM Mg(OAc)2, 0.1% CHAPS, 30 µg/mL BSA, 25 mM HEPES, pH 7.5), phosphate production and MG signal were linear during the reaction time (13.5 minutes), with MG signal below saturation. In a pilot screen containing 1,995 bioactive compounds (MicroSource Spectrum), the signal/background was 80 ± 11 and Z' value was 0.87 ± 0.02 34 . Hence, the assay showed excellent dynamic range and precision, indicating that even weak inhibitors should be detectable.
Hit identification.
Having established that the MG assay quantitatively evaluates RAD54 ATPase activity, we performed a high-throughput screen (HTS) of 104,286 commercially sourced molecules. Compounds were screened at 10 µM. Due to a lower signal in the negative controls relative to the pilot screen, the overall S/B ratio = 11 ± 4.5 and Z' = 0.74 ± 0.06 as determined by 10,688 negative (+DNA, DMSO vehicle only; 0 ± 3.1% inhibition, median = -0.1%) and 10,688 positive (no DNA; 100 ± 5.9% inhibition, median = 100%) controls distributed across 334 assay plates (32 of each control per plate) (Fig. 1, Supp. Fig. 4) . Across all 106,281 screened molecules, RAD54 inhibition spanned -16.1% to 99.3% with mean inhibition of -0.76 ± 3.7% (median = -1.1%) (Fig. 1) . We selected 310 (0.3%) molecules with inhibition ≥17.7% (≥3 s.d. from the mean of the 100% inhibition controls), with activities ranging from 17.7 -99.3% inhibition (mean 38.98 ± 20.4% inhibition, median = 31%).
The 310 active compounds were rescreened at seven doses in 2-fold serial dilution to determine the compound IC50 in both the MG assay and in a secondary ATPase assay, ADP-Glo™ (Promega). Assay performance was good for both formats. For MG, the signal/background was 7.5 ± 1.2 and Z' was 0.65 ± 0.09; for ADP-Glo™, the signal/background was 9, with Z' value of 0.74 (ATP depletion ≤5%) (Supp. Fig. 4 and data not shown). Compound IC50 values ranged from <0.31 µM to >20 µM in the MG assay (14 ± 7.1 µM, median = 20 µM) and from <0.63 µM to >30 µM in the ADP-Glo™ assay (15 ± 12 µM, median = 13 µM) (Fig. 1, Supp. Fig. 4) . IC50
values measured in the ADP-Glo™ and MG assays generally correlated for tested compounds (Spearman r = 0.85; Supp. Fig. 4) , although compounds were typically more potent (lower IC50) in ADP-Glo™ assay. For 158 compounds, an IC50 could be determined in both the MG and ADPGlo™ assays, giving a 51% confirmation rate (0.15% of compounds tested in primary screen).
To identify a potential structural basis for inhibition, we examined compounds for common scaffolds using SARvision Plus software. >70% of active molecules binned into scaffold classes comprising ≥3 compounds with ≥2 rings (Supp. Table 1 ). An Excel document summarizing properties identified for the 158 hits is available at https://doi.org/10.7272/Q68G8HW8.
Removal of DNA intercalators and PAINS
DNA binding: DNA dependency of IC50. We next tested for potential artifacts among the confirmed hits by measuring nonspecific binding to DNA. Because RAD54 ATPase activity depended on direct interaction with dsDNA 35, 36 , molecules that intercalated between stacked base pairs or within major or minor DNA grooves could have potentially interfered with RAD54
ATPase activity by altering dsDNA topology through a RAD54-independent mechanism. We Fig. 5 ).
We therefore assayed the 158 confirmed hits in the presence of 125 nM bp pUC19 (DNA lo :
original screening concentration) and 125 µM bp pUC19 (DNA hi : 1,000x) ( Fig. 2A) . Based on their IC50
hi /IC50 lo ratios, hits were clustered into three principal classes with potentially distinct mechanisms of RAD54 inhibition (Fig. 2AB, Supp. Fig. 6 (Fig. 2C) .
TopoI inhibition.
Rather than discount all 38 Class III compounds as non-specific, we applied a second filter based on E. coli Topoisomerase I (TopoI) relaxation of supercoiled pUC19 20 ( Fig.   2E) . Across a titration from 0.1-50 µM, 18 compounds (47% of Class III) interfered with TopoI relaxation of supercoiled DNA at concentrations ≤50 µM and were therefore excluded from further consideration. We also tested all remaining 120 compounds in Classes I and II at a single concentration (50 µM). Surprisingly, we found that 14/92 (15%) of Class I compounds and 10/28 (36%) of Class II compounds also interfered with TopoI relaxation at this concentration; to avoid any nonspecific DNA intercalators, we also excluded these Class I and Class II from further consideration (Fig. 2F) . For the 42 TopoI-interfering compounds from all three classes, the mean (Fig. 1) , of which 26 (81%) were commercially available (www.emolecules.com), purchased and/or resynthesized, tested for purity by LC/MS, and re-evaluated in MG and ADPGlo TM dose response assays. Eleven (42%) repurchased or resynthesized compounds reconfirmed their original activity and were designated as RAD54 inhibitory (54i) molecules (Fig. 1, Supp . Fig. 9) ). Notwithstanding the three computational algorithms to flag PAINS, toxoflavins
were not flagged by any of the technologies, but rather by inspection (as they were discovered as a PAINS class subsequent to the original definition of PAINS substructure rules) 37 . The sizeable fraction of hits tagged as PAINS-like underscores the general importance of marking such molecules early in follow-up to HTS.
Among the eleven RAD54 inhibitory (54i) molecules, nine flagged as PAINS were notable for their generally low IC50 (~1-15 µM, Supp. Table 5 ) and structural similarity and were included at risk in initial exploration of RAD54 inhibitors to cast a wide net; we ultimately discarded these to concentrate on mechanisms specific to interaction with RAD54 (these were designated as 54i P molecules and are not further described outside of Supplement (Supp. Fig. 11, 12, 14) ). Our focus therefore proceeded with two molecules (<0.002% of the library) classified as reproducible, authentic RAD54 inhibitors in vitro (54i compounds: 54i-1, 54i-2; Fig. 3 ). 54i-1 and 54i-2 are structurally distinct Class I compounds. Both meet Lipinski 'rule of 5' (RO5) guidelines for druglikeness (Supp. Fig. 10 ).
Biochemical analysis of 54i compounds
We next set out to investigate the mechanism of inhibition for the reconfirmed RAD54 inhibitors.
54i compounds may inhibit RAD54 ATPase by reversibly or irreversibly interfering with i) RAD54/dsDNA binding or translocation, ii) RAD54 subunit interactions, or iii) ATP binding and hydrolysis. We evaluated reversibility/irreversibility of ATPase inhibition by pre-incubating RAD54 with compound at ten-fold excess to IC50, followed by 100-fold dilution and release into ATPase assays with ATPase recovery monitored over time (so-called "jump dilution assay", Fig.   3 ). We also evaluated interference with RAD54-dsDNA binding by monitoring equilibrium association of RAD54 with dsDNA across a 500-fold compound titration (0 .1-50 µM, Fig. 4 ).
The two Class I compounds 54i-1 (a carbazole) and 54i-2 (an isoquinolyl piperidine) inhibit RAD54 by distinct mechanisms. 54i-1 reversibly inhibits RAD54 with relatively low IC50 (5 ± 1.05 µM), whereas 54i-2 irreversibly inhibits RAD54 with higher IC50 (16 ± 3) (Fig. 3) . 54i-1
does not appear to negate RAD54 binding to dsDNA, but rather provokes higher-order RAD54-dsDNA complexes that are typically more favored at higher RAD54:bp ratios (retained in well);
54i-2, in contrast, interferes with RAD54 complex formation or stability in vitro (Fig. 4) 41 . While 54i-2 did not formally classify as PAINS with the filters used, it was judged to possess other unsavory features, such as potentially electrophilic sites and oxidation-prone ring systems, that make this particular compound less attractive as a starting point for further medicinal chemistry efforts.
We tested toxicity of the 54i cohort in a panel of immortalized cell lines of diverse tissue/tumor origin: embryonic kidney-derived HEK293; karyotypically normal mammary epithelium-derived MCF10A; mammary carcinomas MDA-MB-231, MCF7, HCC1806, and ZR-75-1; fibroblastderived VU423T (BRCA2 -/-), A9.13.423 (VU423T with BRCA2 restored); osteosarcomas U2OS
and Saos2 (both ALT); melanoma LOX; and fibrosarcoma HCT1080 (Supp. Table 9 ). 54i-2 exhibits broad toxicity to tested cell lines, whereas 54i-1 exhibits variable toxicity (Fig. 5 , Supp. Fig. 13 ). Similar to 54i-1 toxicity, cell line sensitivities to three tested genotoxins spanned a broad range of SF50 values, consistent with an expectation that cell type-specific molecular differences mediate diverse tolerance or sensitivity to ICLs (MMC and cisplatin) or PARP inhibition (olaparib). The sensitivity differences observed among tested cell lines are consistent with the broad range of genetic variation recognized in diverse immortalized cell types, and their differential sensitivities to radiation and other genotoxic therapeutics 42 .
When tested in combination with MMC and cisplatin over a 3-day simultaneous exposure protocol in HEK293, 54i-1 and 54i-2 exhibited CI values <1 (stronger effect for cisplatin than MMC), indicating synergism or potentiation with ICL genotoxins that increase demand for intact HR (Z' across all plates = 0.80 ± 0.09, range = 0.58-0.89; S/B = 5 ± 3.5, range = 4.2-5.6) (Fig. 5, Supp. Table 11 , Supp. Fig. 16 ). Further work is needed to define whether the apparent combination interaction is explained by on-target compound interference with HR capacity to complete repair of ICL DNA damage. Importantly, HEK293 sensitivity to chronic ICL treatment is primarily due to proliferative arrest rather than cell death (Supp. Fig. 17 ), suggesting that acute ICL exposure followed by release into proliferative conditions in the presence of 54i compounds may better report on whether 54i compounds interfere with recovery from ICL exposure.
Halogenated tricyclic fused heterocycles
Among the two reproducible 54i hits that emerged from the HTS, 54i-1 (a halogenated carbazole) attracted interest because it does not appear to act as a DNA intercalator (IC50 unaffected by DNA titration, no TopoI inhibition), its cellular toxicity varied across cell types, it mediates weak synergy with cisplatin in a combination assay under a simultaneous exposure protocol, and methods are readily available to prepare substituted carbazoles for evaluation of structure-activity relationships (SAR), selectivity and potency. A 54i-1 analog lacking chlorine atoms on the outer
) exhibited ten-fold lower potency relative to 54i-1, suggesting that a halogenated tricyclic ring system is a key pharmacophore of 54i-1 (Fig. 6A) .
To further explore the role of the tricyclic core and pendant side chain of 54i-1, we synthesized the known 43 dihydroacridine analogs tricyc-1/2/3 ( Fig. 6B) , which bear gem-dimethyl substitution on the central six-membered ring and a pendant side-chain with acidic (tetrazole) rather than the basic functionality of 54i-1. We found that both the acidic side chain and non-planar dihydroacridine core were well tolerated and that halogenation of the distal aromatic rings was correlated with more potent RAD54 inhibition (IC50 ~3-7 µM halogenated [tricyc-2,3] vs. >130
µM non-halogenated [tricyc-1]) (Fig. 6B) . These results suggest that RAD54 inhibition can be mediated by halogenated tricyclic fused heterocycles, and that for carbazole 54i-1 this occurs by a mechanism distinct from DNA intercalation. While the intercalating ability of tricyc-1/2/3 was not explicitly evaluated, 9,9-dimethyl substitution in the central ring is predicted to disfavour if not rule out the possibility of DNA intercalation. In selectivity assays relative to other DNAdependent enzymatic activities that either do not translocate on dsDNA (e.g., HindIII) or that require DNA binding for ATP hydrolysis (e.g., SWI2/SNF2 ATPases S. cerevisiae RAD54, S.
cerevesiae Rdh54, H. sapiens SMARCAL1, and H. sapiens HLTF; non-SWI2/SNF2 ATPases E.
coli RecA and H. sapiens VCP/p97), 54i-1 exhibited similar potency for RAD54 relative to its yeast Rad54 ortholog and for the related human SWI2/SNF2 ATPase SMARCAL1, ~10-fold greater potency relative to its yeast Rdh54 homolog, ~100-fold greater potency relative to the related human SWI2/SNF2 ATPase HLTF and the unrelated human AAA ATPase VCP/p97, but nearly 5-fold lower potency relative to the unrelated E. coli ssDNA-dependent ATPase RecA (Fig.   6CD , Supp. Table 12 ). The differential selectivity among human SWI2/SNF2 ATPases, VCP/p97, and RecA indicates that further improvements in selectivity can likely be achieved. In continued work, it will be important to complete binding kinetics (e.g., microscale thermophoresis)
to test direct interaction and complete further structure-activity studies.
Prospects for HR inhibition
The 54i molecules described here were identified in an effort to uncover chemotypes that interfere with a human HR-associated ATPase, RAD54. Because RAD51 and RAD54 ATPases collaborate in HR, inhibitors of either ATPase may have therapeutic applications in oncology. For RAD51, several reported small molecule modulators demonstrate that multiple biochemical activities of the enzyme can be altered (ssDNA binding, dsDNA binding, oligomerization) by covalent or noncovalent interactions, and can yield distinct mechanistic consequences to filament maturation (e.g., blocking ssDNA binding), homologous pairing or hDNA formation in vitro; some of these molecules reduce RAD51 foci in vivo, potentiating ICL sensitivity
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. For RAD54, the mitomycin C-and actinomycin-related aminoquinone streptonigrin has been reported to inhibit the SWI2/SNF2 ATPase but not RAD51
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. Whether any RAD51-or RAD54-inhibiting compound specifically impairs HR in vivo, however, remains to be determined. Unlike RAD51, RAD54 and its paralog RAD54B engage in synthetic lethal interactions that suggest that their inhibition accumulates potentially toxic HR intermediates 33, 46 . Like RAD51, RAD54 exhibits mechanistically separable biochemical activities that can be potentially targeted for interference, warranting continued efforts to identify distinct molecules that interfere with orthogonal functions such as DNA binding, oligomerization, ATPase activity, DNA translocation, and interaction/modulation by other factors like RAD51.
In sum, our screen for RAD54 ATPase inhibitors yielded two validated inhibitors of human RAD54. Although these compounds have potential limitations (toxicity, reactivity), the 54i molecules reported here (54i-1-2) represent novel structures that were vetted for DNA intercalation and PAINS. The activity of 54i-1 and tricyc-1-3 suggests that halogenated tricyclic heterocycles differentially inhibit human Swi2/Snf2 ATPases, and may merit analysis in assays that report on HR function in vivo. compound interference with RAD54-dsDNA binding equilibrium state; 54i-1 does not negate RAD54 binding to dsDNA (but rather appears to promote higher-order RAD54-dsDNA binding), whereas 54i-2 interferes with RAD54-dsDNA interaction across the compound titration. RAD54
was set to 25 bp:1 RAD54 (monomer) and compounds were titrated from 0.1 to 50 µM. eMolecules (24) resynthesis (2) TopoI inhibition 
